nevirapine has been researched along with Kaposi Sarcoma in 8 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " As of September 1, 1996, ADAP began covering HIV protease inhibitors, viral load evaluations, and other crucial anti-HIV and opportunistic infection agents, including nevirapine for HIV, cidofovir for CMV, and DaunoXome for Kaposi's sarcoma." | 3.69 | New York ADAP to cover new AIDS drugs plus viral load testing. ( Link, D, 1996) |
| "The optimal approach to HIV-associated Kaposi sarcoma (HIV-KS) in sub-Saharan Africa is unknown." | 2.77 | A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. ( Aboobaker, J; Coovadia, HM; Esterhuizen, T; Friedland, GH; Mosam, A; Scadden, DT; Shaik, F; Uldrick, TS, 2012) |
| "HIV-associated Kaposi sarcoma (HIV-KS) is the most common cancer in Malawi." | 1.42 | Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. ( Bazile, J; Beste, JA; Chingoli, F; Crocker, JT; Elmore, SN; Gopal, S; Herce, ME; Kalanga, N; Keck, JW; Mailosi, B; Phiri, A; Rigodon, J; Tengatenga, L; Wroe, EB, 2015) |
| "A retrospective cohort of 124 AIDS patients initiating ART under routine practice conditions was studied." | 1.39 | AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe. ( Borok, MZ; Campbell, TB; Makadzange, AT; Mhlanga, TO; Nelson, BC, 2013) |
| "We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction." | 1.33 | No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. ( Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nelson, BC | 1 |
| Borok, MZ | 1 |
| Mhlanga, TO | 1 |
| Makadzange, AT | 1 |
| Campbell, TB | 1 |
| Herce, ME | 1 |
| Kalanga, N | 1 |
| Wroe, EB | 1 |
| Keck, JW | 1 |
| Chingoli, F | 1 |
| Tengatenga, L | 1 |
| Gopal, S | 1 |
| Phiri, A | 1 |
| Mailosi, B | 1 |
| Bazile, J | 1 |
| Beste, JA | 1 |
| Elmore, SN | 1 |
| Crocker, JT | 1 |
| Rigodon, J | 1 |
| Mosam, A | 1 |
| Shaik, F | 1 |
| Uldrick, TS | 1 |
| Esterhuizen, T | 1 |
| Friedland, GH | 1 |
| Scadden, DT | 1 |
| Aboobaker, J | 1 |
| Coovadia, HM | 1 |
| Kappelhoff, BS | 1 |
| Huitema, AD | 1 |
| Mairuhu, AT | 1 |
| Schellens, JH | 1 |
| Beijnen, JH | 1 |
| Erlander, SR | 1 |
| Shaw, AJ | 1 |
| McLean, KA | 1 |
| Link, D | 1 |
1 trial available for nevirapine and Kaposi Sarcoma
| Article | Year |
|---|---|
A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa.
Topics: Adult; Anti-HIV Agents; Antigens, Neoplasm; Antiretroviral Therapy, Highly Active; Drug Therapy; Fem | 2012 |
7 other studies available for nevirapine and Kaposi Sarcoma
| Article | Year |
|---|---|
AIDS-associated Kaposi sarcoma: outcomes after initiation of antiretroviral therapy at a university-affiliated hospital in urban Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; | 2013 |
Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Retrosp | 2015 |
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450 | 2005 |
The eighth mystery of acquired immune deficiency syndrome and the "Trojan horse' mechanism.
Topics: Acquired Immunodeficiency Syndrome; Apoptosis; CD4-Positive T-Lymphocytes; Endopeptidases; Eosinophi | 1996 |
Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirapine; Reverse | 1999 |
New York ADAP to cover new AIDS drugs plus viral load testing.
Topics: Acquired Immunodeficiency Syndrome; Antibiotics, Antineoplastic; Antiviral Agents; Cytomegalovirus I | 1996 |
FDA news. Food and Drug Administration.
Topics: Antineoplastic Agents; Child; Dermatologic Agents; Drug Approval; HIV Infections; Humans; Nevirapine | 1999 |